Back to Search Start Over

Characterization of cytokeratin 19-positive hepatocyte foci in the regenerating rat liver after 2-AAF/CCl4 injury

Authors :
Shiu Huey Chou
Ding-Shinn Chen
Chien Chang Chiu
Ling Ling Chiou
Hsuan-Shu Lee
Chiang Ting Chien
Guan-Tarn Huang
Mei-Hwei Chang
Source :
Histochemistry and Cell Biology. 128:217-226
Publication Year :
2007
Publisher :
Springer Science and Business Media LLC, 2007.

Abstract

Partial hepatectomy or carbon tetrachloride (CCl4) injury, following treatment of rats with 2-acetylaminofluorene (2-AAF) to inhibit proliferation of hepatocytes, induces proliferation of oval cells and possibly their differentiation into nodular foci of hepatocytes when higher doses of 2-AAF are used. Unfortunately, immunohistochemistry in previous studies failed to show oval cell markers in these foci, and thereby to demonstrate the precursor-product relationship between oval cells and hepatocytes. Immunohistochemistry on livers of rats treated with high dose 2-AAF/CCl4 was used. We found 7.6% of the hepatocyte foci were positive for an oval cell marker cytokeratin 19 (CK-19). These foci were positive for alpha-fetoprotein, less positive for carbamoylphosphate synthetase 1, and more positive for laminin in the basement membrane lining. Rarely present transitional foci had weaker expression of CK-19 and discontinuous laminin. Focal hepatocyte differentiation of oval cells was characterized by cell hypertrophy, membranous CK-19, and positive hepatocyte nuclear factor 4 (HNF-4). HNF-4+ small oval cells surrounding CK-19+ foci were frequently seen, suggesting that a paracrine mechanism(s) may be responsible for the enlargement of CK-19+ foci. In conclusions, oval cells appear to differentiate to CK-19+ foci and then to CK-19- foci in the high dose 2-AAF/CCl4 model.

Details

ISSN :
1432119X and 09486143
Volume :
128
Database :
OpenAIRE
Journal :
Histochemistry and Cell Biology
Accession number :
edsair.doi.dedup.....9c10ec9dbb2d1924aa96431639f2da6f
Full Text :
https://doi.org/10.1007/s00418-007-0309-3